Immediate and Long-term Hemodynamic and Clinical Effects of Sildenefil in Patients With Pulmonary Arterial Hypertension Receiving Vasodilator Therapy

Bhatia, Sundeep; Frantz, Robert P.; Severson, Cathy J.; Durst, Louise A.; McGoon, Michael D.
October 2003
Mayo Clinic Proceedings;Oct2003, Vol. 78 Issue 10, p1207
Academic Journal
Determines the immediate and long-term effects of adding sildenefil, a phosphodiesterase-5 inhibitor to the medical regimen of patients with pulmonary arterial hypertension (PAH). Pulmonary vasodilator effect in patients already receiving vasodilators for PAH.


Related Articles

  • Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study. Jing, Z.-C.; Jiang, X.; Wu, B.-X.; Xu, X.-Q.; Wu, Y.; Ma, C.-R.; Wang, Y.; Yang, Y.-J.; Pu, J.-L.; Gao, W. // Heart;Sep2009, Vol. 95 Issue 18, p18 

    Background: Vardenafil is a new phosphodiesterase-5 inhibitor that has shown some efficacy in the treatment of pulmonary arterial hypertension (PAH). Objective: To examine the long-term effects of vardenafil in patients with PAH. Methods: A multicentre, open-label study of 1-year's duration was...

  • Acute Pulmonary Embolism Decreases Adenosine Plasma Levels in Anesthetized Pigs. Kerbaul, Francois; By, Youlet; Gariboldi, Vlad; Mekkaoui, Choukri; Fesler, Pierre; Collart, Frédéric; Brimioulle, Serge; Jammes, Yves; Ruf, Jean; Guieu, Régis // ISRN Cardiology;2011, Special section p1 

    Adenosine plays a role in pulmonary arterial (PA) resistance due to its vasodilator properties. However, the behavior of adenosine plasma levels (APLs) during pulmonary embolism remains unknown. We investigated the effects of gradual pulmonary embolism on right ventricular (RV) contractility and...

  • Recent Advances in the Management of Pulmonary Arterial Hypertension. Papadakis, Emmanuel; Michalopoulos, Argyris // Current Respiratory Medicine Reviews;2009, Vol. 5 Issue 1, p41 

    Conventional treatment of pulmonary arterial hypertension (PAH) includes oxygen supplementation, calcium channel blockers, anticoagulation, digoxin, and diuretics. Calcium channel blockers have little or no effect on the majority of patients with moderate or severe PAH. Apart from the...

  • The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension. Fan, You-Fei; Zhang, Rui; Jiang, Xin; Wen, Li; Wu, Dan-Chen; Liu, Dong; Yuan, Ping; Wang, Yu-Lin; Jing, Zhi-Cheng // Cardiovascular Research;Aug2013, Vol. 99 Issue 3, p395 

    Aims Oxidative stress is implicated in the pathology of pulmonary arterial hypertension (PAH). Previously, we demonstrated that vardenafil, a phosphodiesterase-5 inhibitor, has potential as therapy for PAH, although the mechanism remained uncharacterized. Here, we aimed to determine baseline...

  • Sitaxsentan. Reinhart, Kurt; White, C. Michael // Formulary;May2007, Vol. 42 Issue 5, p295 

    Elevated blood pressure in the pulmonary vasculature, known as pulmonary arterial hypertension (PAH), stresses the right side of the heart and can increase the risk for functional disability and death. In advanced disease, several drugs can be employed, including calcium-channel blockers,...

  • THERAPEUTIC APPROACHES FOR THE TREATMENT OF PULMONARY HYPERTENSION. Malaeb, Diana; Sakr, Fouad; Dabbous, Mariam // International Journal of Pharmacy;2013, Vol. 3 Issue 3, p436 

    Pulmonary hypertension is a progressive symptomatic fatal disease. It is a diagnosis of exclusion. The main goal of therapy is to lower pulmonary arterial pressure and pulmonary vascular resistance while preserving systemic pressure. Current treatments including calcium channel blockers,...

  • Physicochemical and Microbiological Stability of the Extemporaneous Sildenafil Citrate Oral Suspension. Attawadee SAE YOON; Somchai SAWATDEE; Chuthamas WORADECHAKUL; Kridsada SAE CHEE; Apichart ATIPAIRIN // Scientia Pharmaceutica;Oct-Dec2015, Vol. 83 Issue 4, p659 

    Sildenafil is a potent and selective phosphodiesterase-5 inhibitor that is effectively used in the treatment of pulmonary arterial hypertension. In several countries, hospital pharmacists prepare the drug in an extemporaneous liquid preparation as there are no liquid formulations available for...

  • Prostacyclin Therapy for Pulmonary Arterial Hypertension. Ruan, Cheng-Huai; Dixon, Richard A.F.; Willerson, James T.; Ruan, Ke-He // Texas Heart Institute Journal;2010, Vol. 37 Issue 4, p391 

    In pulmonary arterial hypertension, the blood vessels that carry blood between the heart and lungs are constricted, making it difficult for the heart to pump blood through the lungs. Prostacyclin, a prostanoid metabolized from endogenous arachidonic acid through the cyclooxygenase (COX) pathway,...

  • Correlación clínica-hemodinámica de la clasificación de la NYHA/WHO en enfermos con hipertensión arterial pulmonar idiopática. Sus implicaciones en la clínica, en el tratamiento y en el pronó... Herrera, Eulo Lupi; Zárate, Julio Sandoval; Solano, Javier Figueroa; Santos Martínez, Luis Efrén; Pulido Zamudio, Tomás René; Bautista Bautista, Edgar Gildardo // Archivos de Cardiología de México;abr-jun2008, Vol. 78 Issue 2, p148 

    Background: The most often used functional classification for categorizing the degree of cardiac disability in patients with chronic left ventricular failure is the NYHA/WHO system . In Idiopathic Pulmonary Arterial Hypertension [IPAH], this system although used, has not been studied in detail...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics